| A large number of antibodies |
Extremely high affinity |
Delivery of dozens to
hundreds of lead antibodies |
nM to sub-nM level for
the affinity of lead antibodies |
 |
 |
| Diversified screening |
Drug developability guarantee |
Cross-reactivity of species
guaranteed through multiple
immunology strategies combined
with multiple screening methods. |
Drug developability guaranteed
through multi-dimensional
testing of lead antibodies. |
 |
 |
| Rich experience |
Delivered within 12–15 weeks |
Assist customers in the IND filing
of several drugs and the publication
of a number of articles
in high impact factor journals |
High-throughput and automated
batch screening, which helps
to save 3 months compared
to hybridoma technology. |
 |
 |